Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on, open-label, phase III study of CS-866AZ
jRCT2080220290Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olmesartan medoxomil + azelnidipine in essential hypertension, sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
olmesartan medoxomil + azelnidipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080220290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220290.